oxidopamine has been researched along with Ambulation Disorders, Neurologic in 16 studies
Oxidopamine: A neurotransmitter analogue that depletes noradrenergic stores in nerve endings and induces a reduction of dopamine levels in the brain. Its mechanism of action is related to the production of cytolytic free-radicals.
oxidopamine : A benzenetriol that is phenethylamine in which the hydrogens at positions 2, 4, and 5 on the phenyl ring are replaced by hydroxy groups. It occurs naturally in human urine, but is also produced as a metabolite of the drug DOPA (used for the treatment of Parkinson's disease).
| Excerpt | Relevance | Reference |
|---|---|---|
| "The abnormal involuntary movements scale measured L-DOPA and dopamine D1- and D2-receptor agonist-induced dyskinesia." | 1.62 | Effects of pedunculopontine nucleus cholinergic lesion on gait and dyskinesia in hemiparkinsonian rats. ( Bishop, C; Chambers, NE; Clark, SD; Coyle, M; Lanza, K; Saito, C; Sergio, J; Topping, B, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (25.00) | 29.6817 |
| 2010's | 11 (68.75) | 24.3611 |
| 2020's | 1 (6.25) | 2.80 |
| Authors | Studies |
|---|---|
| Xu, M | 1 |
| Bohlen, JK | 1 |
| Moore, C | 1 |
| Nipper, MA | 1 |
| Finn, DA | 1 |
| Jones, CE | 1 |
| Lim, MM | 1 |
| Meshul, CK | 1 |
| Chambers, NE | 1 |
| Coyle, M | 1 |
| Sergio, J | 1 |
| Lanza, K | 1 |
| Saito, C | 1 |
| Topping, B | 1 |
| Clark, SD | 1 |
| Bishop, C | 1 |
| Baufreton, J | 1 |
| Milekovic, T | 1 |
| Li, Q | 1 |
| McGuire, S | 1 |
| Moraud, EM | 1 |
| Porras, G | 1 |
| Sun, S | 1 |
| Ko, WKD | 1 |
| Chazalon, M | 1 |
| Morin, S | 1 |
| Normand, E | 1 |
| Farjot, G | 1 |
| Milet, A | 1 |
| Pype, J | 1 |
| Pioli, E | 1 |
| Courtine, G | 1 |
| Bessière, B | 1 |
| Bezard, E | 1 |
| Tsang, AR | 1 |
| Rajakumar, N | 1 |
| Jog, MS | 1 |
| Loiodice, S | 1 |
| Wing Young, H | 1 |
| Rion, B | 1 |
| Méot, B | 1 |
| Montagne, P | 1 |
| Denibaud, AS | 1 |
| Viel, R | 1 |
| Drieu La Rochelle, C | 1 |
| Ouachikh, O | 1 |
| Dieb, W | 1 |
| Durif, F | 1 |
| Hafidi, A | 1 |
| Silvestrin, RB | 1 |
| de Oliveira, LF | 1 |
| Batassini, C | 1 |
| Oliveira, A | 1 |
| e Souza, TM | 1 |
| Chuang, CS | 1 |
| Su, HL | 1 |
| Cheng, FC | 1 |
| Hsu, SH | 1 |
| Chuang, CF | 1 |
| Liu, CS | 1 |
| Hsieh, TH | 1 |
| Chen, JJ | 1 |
| Chen, LH | 1 |
| Chiang, PT | 1 |
| Lee, HY | 1 |
| Glajch, KE | 1 |
| Fleming, SM | 1 |
| Surmeier, DJ | 1 |
| Osten, P | 1 |
| Lindemann, C | 1 |
| Krauss, JK | 1 |
| Schwabe, K | 1 |
| Kaindlstorfer, C | 1 |
| García, J | 1 |
| Winkler, C | 1 |
| Wenning, GK | 1 |
| Nikkhah, G | 1 |
| Döbrössy, MD | 1 |
| Tai, CH | 1 |
| Pan, MK | 1 |
| Lin, JJ | 1 |
| Huang, CS | 1 |
| Yang, YC | 1 |
| Kuo, CC | 1 |
| Lebsanft, HB | 1 |
| Kohles, T | 1 |
| Kovar, KA | 1 |
| Schmidt, WJ | 1 |
| Han, F | 1 |
| Wang, H | 1 |
| Vlamings, R | 1 |
| Visser-Vandewalle, V | 1 |
| Koopmans, G | 1 |
| Joosten, EA | 1 |
| Kozan, R | 1 |
| Kaplan, S | 1 |
| Steinbusch, HW | 1 |
| Temel, Y | 1 |
16 other studies available for oxidopamine and Ambulation Disorders, Neurologic
| Article | Year |
|---|---|
Effects of sleep disruption on stress, nigrostriatal markers, and behavior in a chronic/progressive MPTP male mouse model of parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Corticosterone; Disease Mode | 2019 |
Effects of pedunculopontine nucleus cholinergic lesion on gait and dyskinesia in hemiparkinsonian rats.
Topics: Animals; Cholinergic Agents; Disease Models, Animal; Dyskinesias; Gait; Gait Disorders, Neurologic; | 2021 |
Inhaling xenon ameliorates l-dopa-induced dyskinesia in experimental parkinsonism.
Topics: Administration, Inhalation; Animals; Antiparkinson Agents; Disease Models, Animal; Dose-Response Rel | 2018 |
Intrapallidal injection of botulinum toxin A recovers gait deficits in a parkinsonian rodent model.
Topics: Animals; Botulinum Toxins, Type A; Entopeduncular Nucleus; Gait Disorders, Neurologic; Oxidopamine; | 2019 |
Implication of nigral dopaminergic lesion and repeated L-dopa exposure in neuropsychiatric symptoms of Parkinson's disease.
Topics: Amphetamine; Animals; Antiparkinson Agents; Anxiety; Benserazide; Disease Models, Animal; Dopamine; | 2019 |
Differential behavioral reinforcement effects of dopamine receptor agonists in the rat with bilateral lesion of the posterior ventral tegmental area.
Topics: Adrenergic Agents; Analysis of Variance; Animals; Body Weight; Brain; Cocaine; Conditioning, Operant | 2013 |
The footfault test as a screening tool in the 6-hydroxydopamine rat model of Parkinson's disease.
Topics: Animals; Behavior, Animal; Behavioral Sciences; Disease Models, Animal; Dopamine; Dopamine Agonists; | 2009 |
Quantitative evaluation of motor function before and after engraftment of dopaminergic neurons in a rat model of Parkinson's disease.
Topics: Adrenergic Agents; Animals; Disease Models, Animal; Dopamine; Embryonic Stem Cells; Female; Gait; Ga | 2010 |
Time-course gait analysis of hemiparkinsonian rats following 6-hydroxydopamine lesion.
Topics: Analysis of Variance; Animals; Apomorphine; Disease Models, Animal; Disease Progression; Functional | 2011 |
Sensorimotor assessment of the unilateral 6-hydroxydopamine mouse model of Parkinson's disease.
Topics: Adrenergic Agents; Animals; Disease Models, Animal; Dopaminergic Neurons; Gait Disorders, Neurologic | 2012 |
Deep brain stimulation of the subthalamic nucleus in the 6-hydroxydopamine rat model of Parkinson's disease: effects on sensorimotor gating.
Topics: Acoustic Stimulation; Analysis of Variance; Animals; Deep Brain Stimulation; Disease Models, Animal; | 2012 |
Behavioral and histological analysis of a partial double-lesion model of parkinson-variant multiple system atrophy.
Topics: Animals; Apomorphine; Cell Count; Corpus Striatum; Disease Models, Animal; Dopamine Agonists; Dopami | 2012 |
Subthalamic discharges as a causal determinant of parkinsonian motor deficits.
Topics: Action Potentials; Animals; Animals, Newborn; Biophysics; Deep Brain Stimulation; Disease Models, An | 2012 |
3,4-Methylenedioxymethamphetamine counteracts akinesia enantioselectively in rat rotational behavior and catalepsy.
Topics: Adrenergic Uptake Inhibitors; Animals; Antiparkinson Agents; Behavior, Animal; Catalepsy; Denervatio | 2005 |
Effects of desensitized nicotinic receptors on rotational behavior in a 6-hydroxydopamine model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Brain; Disease Models, Animal; Dopamine Agonists; D | 2007 |
High frequency stimulation of the subthalamic nucleus improves speed of locomotion but impairs forelimb movement in Parkinsonian rats.
Topics: Animals; Corpus Striatum; Denervation; Disease Models, Animal; Dopamine; Electric Stimulation Therap | 2007 |